ReviewDigestive diseases and sciences2016
Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.
Review in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 58 citations in OpenAlex.
- Essential amino acid enriched meal replacement improves body composition and physical function in obese older adults: A randomized controlled trial.Clinical nutrition ESPEN · 2022Trial
- Metabolic comorbidities and post-transplant outcomes in Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD): a cohort study from a Brazilian tertiary center.Archives of endocrinology and metabolism · 2025Article
- Review
- Clinical and financial outcomes of transplant recipients following emergency general surgery operations.Surgery open science · 2023Article
- Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease.Euroasian journal of hepato-gastroenterology · 2022Review
- Noninvasive markers of liver steatosis and fibrosis after liver transplantation - Where do we stand?World journal of transplantation · 2021Review
- Mechanisms of nonalcoholic fatty liver disease and implications for surgery.Langenbeck's archives of surgery · 2021Review
- Bariatric Surgery Outcomes in Patients with Previous Organ Transplant: Scoping Review and Analysis of the MBSAQIP.Obesity surgery · 2021Article
- Liver transplantation and aging.World journal of transplantation · 2020Review
- Article
- Review
- Review
- Low fat but not soy protein isolate was an effective intervention to reduce nonalcoholic fatty liver disease progression in C57BL/6J mice: monitored by a novel quantitative ultrasound (QUS) method.Nutrition research (New York, N.Y.) · 2019Article
- Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft.Journal of clinical and translational hepatology · 2018Review
- Observational
- Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?World journal of gastroenterology · 2018Review
- Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do.World journal of hepatology · 2017Review
- Bariatric Surgery and Liver Transplantation.Gastroenterology & hepatology · 2017Article
- The role of extended criteria donors in liver transplantation for nonalcoholic steatohepatitis.Surgery · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common etiology of chronic liver disease in developed countries and is on trajectory to become the leading indication for liver transplantation in the USA and much of the world. Patients with NAFLD cirrhosis awaiting liver transplant face unique challenges and increased risk for waiting list stagnation and dropout due to burdensome comorbidities including obesity, diabetes, cardiovascular disease, and kidney disease. Thus far, patients transplanted for NAFLD cirrhosis have excellent mid- and long-term patient and graft survival, but concerns regarding short-term morbidity and mortality continue to exist. Post-liver transplantation, NAFLD occurs as both a recurrent and de novo manifestation, each with unique outcomes. NAFLD in the donor population is of concern given the growing demand for liver transplantation and mounting pressure to expand the donor pool. This review addresses key issues surrounding NAFLD as an indication for transplantation, including its increasing prevalence, unique patient demographics, outcomes related to liver transplantation, development of post-liver transplantation NAFLD, and NAFLD in the liver donor population. It also highlights exciting areas where further research is needed, such as the role of bariatric surgery and preconditioning of marginal donor grafts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.